Hormone receptor-positive, HER2-positive breast cancer with later lung metastasis

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Hormone receptor-positive; HER2-positive

Metastatic Site: Lung

The patient had hormone receptor-positive, HER2-positive breast cancer treated with standard therapy, then developed lung metastasis years later and continued molecular targeted therapy indefinitely while asymptomatic from the metastasis.

Stage IV HER2-Positive Breast Cancer: Pilar's Patient Story

Patient Info: Pilar, Female, 40s | Stage IV

Biomarkers: Hormone receptor-positive; HER2-positive

Pilar was living with metastatic hormone receptor-positive, HER2-positive breast cancer, continuing systemic treatment with Zoladex, aromatase inhibitors, trastuzumab, and pertuzumab, and managing side effects with rehabilitation support.

Stage III Breast Cancer: Cher's Survivor Story

Patient Info: Cher, Female | Stage III

Biomarkers: Hormone-positive; HER2-negative; Oncotype DX score 0

No evidence of disease after treatment for Stage IIIB breast cancer, with ongoing adjuvant Verzenio, long-term hormone blockers, and planned preventive mastectomy/DIEP flap reconstruction.

breastcancer.orgRead more →

Stage I Breast Cancer: Michelle's Survivor Story

Patient Info: Michelle Kang, Female, Under 40 | Stage I

Biomarkers: Hormone-positive breast cancer; no suspicious inherited genetic mutation reported

Michelle was 6 years cancer-free after Stage 1B hormone-positive breast cancer while continuing hormone therapy, Zometa, Signatera blood testing, reconstruction follow-up, and survivorship monitoring.

City of HopeRead more →

Hormone receptor-positive, HER2-positive breast cancer treatment interrupted by vaginal cuff dehiscence and bowel evisceration

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: Hormone receptor-positive; HER2-positive

At 21 months after emergency repair, she was symptom-free with POP-Q stage 0; letrozole continued and T-DM1 was resumed 7 weeks after discharge, but long-term cancer response was not detailed.

PubMed CentralRead more →

Stage IV Breast Cancer: Abigail's Patient Story

Patient Info: Abigail, Female, Under 40 | Stage IV

Biomarkers: Strongly hormone-positive; germline ATM mutation

Metastatic Site: Bones

As of June 2026, Abigail was living with Stage IV metastatic hormone-positive breast cancer with bone metastases after diagnosis at 38 and lumpectomy in June 2017.

The Patient StoryRead more →

Stage II HR-Positive Breast Cancer: Bethany's Patient Story

Patient Info: Bethany W., Female, Under 40 | Stage II

Biomarkers: ER-positive; hormone-positive

As of June 2026, Bethany described care for late Stage II/early Stage III ER-positive breast cancer, beginning with AC chemotherapy and Taxol after scans showed no distant spread, with surgery, radiation, and hormone therapy planned as next phases.

The Patient StoryRead more →

Stage IV HR-Positive Breast Cancer: Joelle's Patient Story

Patient Info: Joelle, Female, Under 40 | Stage IV

Biomarkers: HR-positive / hormone-positive

Metastatic Site: Bone/hip; lymph nodes; other sites not specified

Living with Stage IV hormone-positive breast cancer on ongoing systemic therapy and monitoring, with tumor-marker checks every 3 months and scans every 6 months; no remission or NED status is stated.

The Patient StoryRead more →

Stage IV Breast Cancer: Erica's Patient Story

Patient Info: Erica, Female, 40s | Stage IV

Biomarkers: Hormone-positive; HER2-negative

Metastatic Site: Bone — ribs, sternum, spine, femur/right hip, shoulder…

Living with stable Stage IV hormone-positive, HER2-negative metastatic breast cancer involving multiple bones, currently managed with monthly hormone-suppressant injections and monitoring.

The Patient StoryRead more →

Stage III HER2-Positive Breast Cancer: Caroline's Patient Story

Patient Info: Caroline McNally, Female, Under 40 | Stage III

Biomarkers: Hormone-positive component reported; exact ER/PR/HER2 panel not stated

As of February 2026, Caroline was in active treatment for Stage III hormone-positive breast cancer, receiving Taxol after dose-dense AC and preparing for double mastectomy, likely radiation, and hormone therapy.

Hormone receptor-positive breast cancer treated with pembrolizumab trial complicated by acquired lipodystrophy

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-negative breast cancer. Metabolic changes occurred during/after pembrolizumab.

As of December 2025, breast cancer treatment had included neoadjuvant chemotherapy/pembrolizumab, surgery, adjuvant pembrolizumab, and endocrine therapy; CT did not show recurrence during weight-loss evaluation, but she required ongoing metabolic care for pembrolizumab-associated acquired generalized lipodystrophy.

PubMed CentralRead more →

Stage III Invasive Lobular Carcinoma: Stacy's Survivor Story

Patient Info: Stacy, Female | Stage III

Biomarkers: Hormone receptor-positive; HER2-negative

Stacy completed chemotherapy, mastectomy, radiation and reconstruction. She remained under regular monitoring and was taking Letrozole as part of a planned 10-year course.

Lobular Breast Cancer AllianceRead more →

Breast Cancer: Theresa's Survivor Story

Patient Info: Theresa, Female, 40s

Biomarkers: Hormone receptor-positive; exact receptors not fully specified

Theresa completed treatment for multiple cancers, including bilateral mastectomy/reconstruction for breast cancer and later excision plus 3 months of radiation for chest-wall recurrence. As of October 2025, she described being about 6 years out from the later recurrence, with no other cancer found on scans.

The Patient StoryRead more →

Stage IV HER2-Positive Breast Cancer: Kathleen's Patient Story

Patient Info: Kathleen McEvoy-Schufreider, female, 60s | Stage IV

Biomarkers: HER2-positive

Metastatic Site: liver, bones

Kathleen continued long-term treatment for metastatic breast cancer, including infusions every 3 weeks after resuming the PATINA regimen outside the trial.

Dana-FarberRead more →

Stage I Breast Cancer: Krista's Patient Story

Patient Info: Krista, Female | Stage I

Biomarkers: ATM mutation; hormone receptor-positive; HER2-negative; Oncotype DX score 1

As of May 2025, Krista had undergone double mastectomy with flap reconstruction for Stage IA hormone receptor-positive, HER2-negative breast cancer and was taking tamoxifen with minimal early side effects.

The Patient StoryRead more →

Stable Metastatic Breast Cancer During Treatment With a CDK4/6 Inhibitor and Fulvestrant

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: HER2-negative

Metastatic Site: liver

Metastatic breast cancer remained stable after 18 months of tiremciclib and fulvestrant.

PubMed CentralRead more →

Breast Cancer Recurring Years Later With Leptomeningeal Spread and a Brief Response to Trastuzumab Deruxtecan

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-low

Metastatic Site: peritoneum, retroperitoneum, bones, leptomeninges

Died on May 10, 2024, about 18 years after her April 2006 breast-cancer diagnosis and about 6 years after metastatic recurrence.

PubMed CentralRead more →

Stage IV Breast Cancer: Kate's Patient Story

Patient Info: Kate, Female, Under 40 | Stage IV

Biomarkers: Hormone-positive

Metastatic Site: Hip bone; lymph nodes near the lungs

Kate remained in active chemotherapy for stage IV disease, with surgery and radiation planned.

The Patient StoryRead more →

Breast Cancer: Krista's Patient Story

Patient Info: Krista Brown, Female

Biomarkers: Pathogenic ATM mutation; hormone receptor-positive; HER2-negative; Oncotype DX score 1/100

As of August 2024, Krista had completed mastectomy/reconstruction surgery and was continuing adjuvant tamoxifen with low reported recurrence risk.

The Patient StoryRead more →

Stage IV Breast Cancer: Samantha's Patient Story

Patient Info: Samantha, Female, Under 40 | Stage IV

Biomarkers: Hormone-positive breast cancer; specific receptor details not reported

Metastatic Site: bone: rib, spine, pelvis

As of July 2024, Samantha was living with Stage IV hormone-positive breast cancer with bone metastases. Current treatment was working in most areas, but a breast tumor continued to grow and was surgically removed; ongoing treatment and 3-month scans were reported.

YouTube — The Patient StoryRead more →

Breast Cancer and a Rare Benign Blood-Vessel Growth Found in the Same Lymph Node

Patient Info: Anonymized, Female, 40s

Biomarkers: HER2-negative

A 47-year-old woman with hormone receptor-positive, HER2-negative breast cancer had five involved axillary lymph nodes, including one that also contained a rare benign hemangioma.

PubMed CentralRead more →

At 40, a Tumor Test Supported Chemotherapy for Rare Neuroendocrine Breast Cancer

Patient Info: Anonymized, Female, 40s

Biomarkers: Chromogranin strongly positive; synaptophysin strongly positive; ER score 300; PR score 240; HER2-negative; Ki-67 35%; Oncotype DX Recurrence Score 38

A 40-year-old with a 1.4 cm, node-negative neuroendocrine breast tumor had a high Oncotype DX score of 38, supporting chemotherapy.

PubMed CentralRead more →

At 45, a Tumor Test Supported Chemotherapy for Rare Neuroendocrine Breast Cancer

Patient Info: Anonymized, Female, 40s

Biomarkers: Chromogranin strongly positive; synaptophysin strongly positive; ER score 300; PR score 270; HER2-negative; Ki-67 40%; Oncotype DX Recurrence Score 32

A 45-year-old with a 2.0 cm, node-negative neuroendocrine breast tumor had a high Oncotype DX score of 32, supporting chemotherapy.

PubMed CentralRead more →

At 53, a Tumor Test Suggested Chemotherapy Could Be Avoided for Rare Breast Cancer

Patient Info: Anonymized, Female, 50s

Biomarkers: Chromogranin strongly positive; synaptophysin strongly positive; ER score 285; PR score 300; HER2-negative; Ki-67 40%; Oncotype DX Recurrence Score 13

A 53-year-old with a 3.0 cm, grade 3 neuroendocrine breast tumor had a low Oncotype DX score of 13, suggesting chemotherapy could be omitted.

PubMed CentralRead more →